Amgen, Inc.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1980-01-01
- Employees
- 26.7K
- Market Cap
- $175.6B
- Website
- http://www.amgen.com
AMG 510 Ethnic Sensitivity Study (CodeBreaK 105).
- Conditions
- Advanced/Metastatic Solid Tumors With KRAS p.G12C Mutation
- Interventions
- First Posted Date
- 2020-05-08
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Amgen
- Target Recruit Count
- 12
- Registration Number
- NCT04380753
- Locations
- 🇭🇰
University of Hong Kong, Queen Mary Hospital, Hong Kong, Hong Kong
🇨🇳National Taiwan University Hospital, Taipei, Taiwan
🇨🇳Veterans General Hospital - Taichung, Taichung, Taiwan
Study of AMG 256 in Adult Subjects With Advanced Solid Tumors
- First Posted Date
- 2020-04-27
- Last Posted Date
- 2024-10-08
- Lead Sponsor
- Amgen
- Target Recruit Count
- 34
- Registration Number
- NCT04362748
- Locations
- 🇧🇪
Cliniques Universitaires Saint Luc, Bruxelles, Belgium
🇺🇸Washington University, Saint Louis, Missouri, United States
🇪🇸Hospital Clinic i Provincial de Barcelona, Barcelona, Cataluña, Spain
Study to Compare AMG 510 "Proposed INN Sotorasib" With Docetaxel in Non Small Cell Lung Cancer (NSCLC) (CodeBreak 200).
- Conditions
- KRAS p, G12c Mutated /Advanced Metastatic NSCLC
- Interventions
- First Posted Date
- 2020-03-11
- Last Posted Date
- 2025-02-25
- Lead Sponsor
- Amgen
- Target Recruit Count
- 345
- Registration Number
- NCT04303780
- Locations
- 🇧🇪
Institute Jules Bordet, Brussels, Belgium
🇫🇷Centre Hospitalier Intercommunal de Créteil, Créteil, France
🇺🇸James J Peters VA Medical Center, Bronx, New York, United States
Heart Failure Study to Evaluate Vital Signs and Overcome Low Use of Guideline-Directed Therapy by Remote Monitoring
- Conditions
- Heart Failure
- Interventions
- Device: Biobeat Wrist WatchOther: Standard of Care
- First Posted Date
- 2020-03-03
- Last Posted Date
- 2023-08-08
- Lead Sponsor
- Amgen
- Target Recruit Count
- 18
- Registration Number
- NCT04292275
- Locations
- 🇺🇸
Cardiology Associates of Fairfield County, PC, Stamford, Connecticut, United States
🇺🇸Diagnostic Cardiology Group, Chattanooga, Tennessee, United States
🇺🇸Yale New Haven Hospital, New Haven, Connecticut, United States
Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction - DOSE Finding Study
- First Posted Date
- 2020-02-17
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- Amgen
- Target Recruit Count
- 281
- Registration Number
- NCT04270760
- Locations
- 🇳🇱
VieCuri Medisch Centrum, Venlo, Netherlands
🇺🇸Baylor College of Medicine, Houston, Texas, United States
🇺🇸Piedmont Healthcare, Atlanta, Georgia, United States
Biomarker and Genetic Predictors of Erenumab Treatment Response
- First Posted Date
- 2020-02-12
- Last Posted Date
- 2024-06-07
- Lead Sponsor
- Amgen
- Target Recruit Count
- 1406
- Registration Number
- NCT04265755
- Locations
- 🇩🇰
Glostrup Hospital, Glostrup, Denmark
🇮🇸Thjonustumidstod Rannsoknaverkefna, Reykjavik, Iceland
Study of AMG 910 in Subjects With CLDN18.2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma
- Conditions
- Gastric and Gastroesophageal Junction Adenocarcinoma
- Interventions
- First Posted Date
- 2020-02-07
- Last Posted Date
- 2024-01-25
- Lead Sponsor
- Amgen
- Target Recruit Count
- 15
- Registration Number
- NCT04260191
- Locations
- 🇺🇸
Wake Forest Baptist Health, Winston-Salem, North Carolina, United States
🇦🇹Landeskrankenhaus Salzburg, Salzburg, Austria
🇩🇪Klinikum rechts der Isar, München, Germany
Erenumab - Comprehensive Assessment of Efficacy in (High-Frequency) Episodic Migraine
- First Posted Date
- 2020-02-05
- Last Posted Date
- 2023-11-08
- Lead Sponsor
- Amgen
- Target Recruit Count
- 512
- Registration Number
- NCT04252742
- Locations
- 🇺🇸
Chicago Headache Center and Research Institute, Chicago, Illinois, United States
🇺🇸Clinical Research Institute, LLC, Los Angeles, California, United States
🇨🇿Poliklinika Chocen, Neurohk sro, Chocen, Czechia
Single and Multiple Ascending Dose Study of AMG 171 in Subjects With Obesity
- First Posted Date
- 2019-12-13
- Last Posted Date
- 2023-09-15
- Lead Sponsor
- Amgen
- Target Recruit Count
- 60
- Registration Number
- NCT04199351
- Locations
- 🇺🇸
Anaheim Clinical Trials, Anaheim, California, United States
🇺🇸Clinical Pharmacology of Miami, LLC, Miami, Florida, United States
🇺🇸Orange County Research Center, Tustin, California, United States
Study of Early Relapsed, Lenalidomide-refractory Subjects Eligible for Carfilzomib Triplet
- Conditions
- Relapsed or Refractory Multiple Myeloma
- Interventions
- First Posted Date
- 2019-12-10
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Amgen
- Target Recruit Count
- 54
- Registration Number
- NCT04191616
- Locations
- 🇫🇷
Centre Hospitalier Régional Universitaire de Lille - Hôpital Claude Huriez, Lille Cedex, France
🇬🇷University Hospital of Ioannina, Ioannina, Greece
🇮🇹Azienda Unita Sanitaria Locale LE Presidio Ospedaliero Vito Fazzi Polo Oncologico Giovanni Paolo II, Lecce, Italy